<DOC>
	<DOC>NCT01192880</DOC>
	<brief_summary>This Phase 3, multi-center, randomized, double blind, parallel-group, placebo-controlled study will evaluate the efficacy and safety of RO4917838 (bitopertin) in participants with persistent, predominant negative symptoms of schizophrenia. Participants, on stable treatment with antipsychotics, will be randomized to receive daily oral doses of RO4917838 or matching placebo for 52 weeks, followed by an optional treatment extension for up to 3 years.</brief_summary>
	<brief_title>A Study to Evaluate Efficacy and Safety of Bitopertin in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>Based on the screening Structured Clinical Interview for and Statistical Manual of Mental Disorders, 4th Edition (DSM IV) Clinical Trial (SCID CT), a DSMIV Text Revision (DSMIVTR) diagnosis of schizophrenia, paranoid, disorganized, residual, undifferentiated or catatonic subtype A score of 40 or greater on the sum of the 14 PANSS negative and disorganized thought factor items (items scored 17 for a maximum possible score of 98) A score of 22 or less on the sum of the 8 PANSS positive symptom factor items. The score of the items of P1 (delusions), P3 (hallucinatory behavior), P6 (suspiciousness) and G9 (unusual thought content) meet the following requirements: no more than 2 of the above items have a score of 4; all of the above items score less than 5 Clinical stability for 6 months prior to randomization as well as antipsychotic treatment stability for the past 8 weeks at the time of randomization Are at least moderately ill, as defined by Clinical Global Impression Severity (CGI S) of negative symptoms score more than or equal to (&gt;/=) 4 Stable doses of anticholinergic, antidepressive medication for at least 8 weeks prior to randomization is allowed as long as the respective scales cutoff entry criteria are met With the exception of clozapine, participants are on any of the available marketed atypical or typical antipsychotics (treatment with a maximum of 2 antipsychotics) Have a caregiver considered reliable by the investigator Female participants who are not either surgically sterile or postmenopausal must agree to use at least one effective forms of contraception from agree to remain sexually abstinent from screening until 90 days after the completion of the study medication Evidence that participant has clinically significant, uncontrolled and unstable disorder (for example, cardiovascular, renal, hepatic disorder) Body Mass Index (BMI) of less than (&lt;) 17 or more than (&gt;) 40 kilograms per meter square (kg/m^2) Depressive symptoms, defined as a score of 9 or greater on the Calgary Depression Rating Scale for Schizophrenia (CDSS) A severity score of &gt;/=3 on the Parkinsonism item of the Extrapyramidal Symptoms Rating Scale Abbreviated (ESRSA) (Clinical Global Impression, Parkinsonism) Positive result on the serum pregnancy test or are breast feeding at screening, or intend to become pregnant during the course of the trial. History of neuroleptic malignant syndrome (NMS) Based on the DSMIVTR criteria and screening SCIDCT have: other current DSMIVTR Axis I diagnosis; alcohol or substance dependence within 12 months or abuse within 3 months with the exception of nicotine; dementia, delirium and other amnestic disorder per DSMIVTR Treated with electroconvulsive therapy (ECT) within 6 months prior to randomization Ever received RO4917838 or another glycine transporter 1 (GLYT 1) inhibitor Require high doses of benzodiazepines (&gt; 4 mg per day lorazepam or equivalent) Have a positive urine drug screen for amphetamines (including 3,4Methylenedioxymethamphetamine [MDMA]/ecstasy), cocaine, barbiturate, cannabis and/or opiates</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>